A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials

被引:59
作者
Brittain, E [1 ]
Lin, D [1 ]
机构
[1] US FDA, Div Biometr 3, Off Biostat, Ctr Drug Evaluat & Res, Rockville, MD 20850 USA
关键词
non-inferiority trial; design; intent-to-treat; antibiotics;
D O I
10.1002/sim.1934
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
While the intent-to-treat (ITT) analysis is widely accepted for superiority trials, there remains debate about its role in non-inferiority trials. It is often said that the ITT tends to be anti-conservative in the demonstration of non-inferiority. This concern has led to some reliance on per-protocol (PP) analyses that exclude patients on the basis of post-baseline events, despite the inherent bias of such analyses. We compare ITT and PP results from antibiotic trials presented to the public at the FDA's Anti-infective Drug Advisory Committee from 1999 to 2003. While the number of available trials is too small to produce clear conclusions, these data did not support the assumption that the ITT would lead to smaller treatment difference than the PP, in the setting of antibiotic trials. Possible explanations are discussed. Published in 2004 by John Wiley Sons, Ltd.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 9 条
[1]  
[Anonymous], 1998, ICH TOPIC E9 STAT PR
[2]  
*CPMP, 2000, POINTS CONS SWITCH S
[3]   Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics [J].
D'Agostino, RB ;
Massaro, JM ;
Sullivan, LM .
STATISTICS IN MEDICINE, 2003, 22 (02) :169-186
[4]  
Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO
[5]  
2-A
[6]  
*FDA, 1998, FDA ANT DRUG PROD JU
[7]  
*FDA, 2002, FDA ANT DRUG PROD FE
[8]  
*FDA, GUID IND DEV ANT DRU
[9]   Therapeutic equivalence: fallacies and falsification [J].
Garrett, AD .
STATISTICS IN MEDICINE, 2003, 22 (05) :741-762